Giannis Mountzios/LinkedIn
Aug 31, 2025, 14:48
Giannis Mountzios: FLAURA2 vs. MARIPOSA at WCLC25
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“With WCLC25 in 1 week, OS data from FLAURA2 in EGFR + NSCLC are eagerly awaited.
Given that mOS in FLAURA was 38.6m and that mOS in MARIPOSA is projected to exceed 4 years, what would you consider convincing OS to prefer FLAURA2 in PS0/1?”
At the end of his post, Giannis Mountzios included a poll asking: “What would you consider convincing OS to prefer FLAURA2 in PS0/1?”
The options were:
- mOS over 45 months
- mOS over 48 months
- Any Better than MARIPOSA
- Other? Please explain!
More posts featuring Giannis Mountzios on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 31, 2025, 14:48
Aug 31, 2025, 14:17
Aug 31, 2025, 13:57
Aug 31, 2025, 13:49
Aug 31, 2025, 13:38
Aug 31, 2025, 13:37
Aug 31, 2025, 13:10
Aug 31, 2025, 11:58
Aug 31, 2025, 11:44